Compare GPMT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | ENTX |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | Israel |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9M | 58.2M |
| IPO Year | N/A | 2015 |
| Metric | GPMT | ENTX |
|---|---|---|
| Price | $1.41 | $1.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 157.2K | 58.7K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | ★ N/A | $17.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.24 | $0.91 |
| 52 Week High | $3.12 | $3.22 |
| Indicator | GPMT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.78 | 49.46 |
| Support Level | $1.24 | $1.17 |
| Resistance Level | $1.58 | $1.37 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.87 | 27.27 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.